Ventrix, a spin-off company of the University of California San Diego, has developed a special hydrogel that can be injected into the heart to provide a platform for cardiac repair following a heart attack. The technology was just tested in humans for the first time as part of an FDA-approved Phase 1 clinical trial. Though limited in size, the (Read more...)